Alzignomics Gene Therapy RZ-001 Registered as WHO International Nonproprietary Name
Securing Global Official Ingredient Name for RNA-Based Anti-Cancer Gene Therapy
Alzignomics announced on May 27 that the International Nonproprietary Name (INN) for its RNA-based anti-cancer gene therapy 'RZ-001' has been assigned as 'Taspitimagen Advec' by the World Health Organization (WHO). The company explained that it has secured an official ingredient name to be used in global clinical trials and regulatory processes.
The INN is an international standard generic name assigned by the WHO to pharmaceutical ingredients. This system ensures that, even if drugs with the same ingredient are distributed under different names by different countries and companies, they can be consistently identified by a uniform designation.
Alzignomics stated that it was notified by the WHO INN Expert Advisory Panel that the name was selected in accordance with the latest gene therapy naming guidelines. 'Taspitimagen Advec' is scheduled to be listed as a 'Proposed INN' in the upcoming 'WHO Drug Information List 136' to be published this year.
RZ-001 is an RNA-based anti-cancer gene therapy developed using Alzignomics' trans-splicing ribozyme platform technology. It is designed to selectively express therapeutic genes in cancer cells, thereby inducing tumor cell death.
The company is currently conducting clinical trials for glioblastoma and hepatocellular carcinoma after receiving approval from the Ministry of Food and Drug Safety of Korea and the U.S. Food and Drug Administration (FDA). Interim results from the phase 1/2a clinical trial for glioblastoma were presented last year at the European Society for Medical Oncology (ESMO) Asia Congress. For hepatocellular carcinoma, data from the phase 1b/2a clinical trial combining the immuno-oncology drugs atezolizumab and bevacizumab were released in April this year at the American Association for Cancer Research (AACR) annual meeting.
RZ-001 has received FDA Orphan Drug Designation for hepatocellular carcinoma (2024), Fast Track Designation (2025), and Regenerative Medicine Advanced Therapy (RMAT) Designation (2026).
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Bomi Kim, Head of New Drug Development Center at Alzignomics, said, "The INN represents a critical step in transitioning from a development code name to a global product name system," adding, "It will be used as the official name in global regulatory strategies and throughout the development process going forward."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.